Loading…
ImmuCell Corporation is projected to rise to $13.84 by 2027, a +30% move from its current price of $10.63. ICCC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $10.31 | $10.64 | $10.97 | +0.07% |
| May 30 | $10.19 | $10.64 | $11.12 | +0.14% |
| May 31 | $10.10 | $10.65 | $11.24 | +0.21% |
| Jun 1 | $10.02 | $10.66 | $11.34 | +0.28% |
| Jun 2 | $9.95 | $10.67 | $11.43 | +0.35% |
| Jun 3 | $9.90 | $10.67 | $11.51 | +0.42% |
| Jun 4 | $9.84 | $10.68 | $11.59 | +0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.84 | $10.68 | $11.59 | +0.49% |
| Week 2 | $9.56 | $10.73 | $12.05 | +0.98% |
| Week 3 | $9.36 | $10.79 | $12.43 | +1.48% |
| Week 4 | $9.20 | $10.84 | $12.77 | +1.97% |
| Week 5 | $9.07 | $10.89 | $13.08 | +2.47% |
| Week 6 | $8.96 | $10.95 | $13.38 | +2.98% |
| Week 7 | $8.86 | $11.00 | $13.66 | +3.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ImmuCell Corporation is an animal health company that develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E.
coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation.
In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
ImmuCell Corporation, ticker ICCC, currently trades at $10.12 with a market cap of $91.55M and a rank of 4278. The stock’s price today sits within a broader forecast that envisions a strong longer‑term trajectory, albeit with near-term uncertainty.
A major floor 45.1% below — a decisive break under it would weaken the trend.
The nearest floor, 29.1% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 19.4% above — clearing it would confirm fresh momentum.
Key ICCC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ICCC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.23 | Buy | $10.25 | Buy |
| MA 10 | $9.68 | Buy | $9.83 | Buy |
| MA 20 | $9.10 | Buy | $9.24 | Buy |
| MA 50 | $7.85 | Buy | $8.24 | Buy |
| MA 100 | $7.14 | Buy | $7.48 | Buy |
| MA 200 | $6.56 | Buy | $6.82 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 76.12 | Sell |
| Stoch RSI (14) | 96.96 | Sell |
| CCI (20) | 135.17 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 32.05 | Buy |
| Bollinger %B (20,2) | 0.96 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.02 | Buy |
| Awesome (5,34) | 1.68 | Buy |
| Ultimate (7,14,28) | 80.80 | Sell |
| Momentum (10) | 2.25 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 10.59 | Buy |
| ADX (14) | 36.21 | Buy |
| ATR (14) | 0.25 | Info |
The near-term technical picture is bullish, with RSI14 at 70. The stock trades above the 50-day simple moving average of $7.68 and above the 200-day simple moving average of $6.52.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.84 | $10.63 | $14.70 | 0% | Neutral | |
| $10.83 | $13.84 | $18.80 | +30% | Bullish | |
| $13.18 | $17.36 | $24.55 | +63% | Bullish | |
| $15.09 | $20.41 | $29.78 | +92% | Bullish | |
| $20.21 | $27.99 | $41.93 | +163% | Bullish | |
| $23.56 | $33.33 | $51.08 | +214% | Bullish | |
| $23.46 | $33.86 | $52.98 | +219% | Bullish | |
| $26.18 | $38.50 | $61.39 | +262% | Bullish | |
| $27.48 | $41.15 | $66.75 | +287% | Bullish | |
| $33.02 | $50.30 | $82.91 | +373% | Bullish | |
| $48.58 | $80.09 | $141.13 | +653% | Bullish | |
| $101.68 | $192.57 | $373.92 | +17.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.84 | $10.63 | $12.52 | +0.00% |
| June 2026 | $9.40 | $11.07 | $13.37 | +4.15% |
| July 2026 | $9.53 | $11.33 | $13.89 | +2.33% |
| August 2026 | $9.20 | $11.03 | $13.68 | -2.67% |
| September 2026 | $9.15 | $11.03 | $13.81 | +0.03% |
| October 2026 | $9.47 | $11.48 | $14.50 | +4.06% |
| November 2026 | $9.47 | $11.54 | $14.68 | +0.52% |
| December 2026 | $9.37 | $11.47 | $14.70 | -0.56% |
Click any year to see its month-by-month ICCC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ICCC to range from $5.84 to $14.70 through 2026. The $10.63 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ICCC price prediction for 2027 points to an average of $13.84 (low $10.83, high $18.80) — a potential gain of +30% on today's $10.63. Momentum favours further upside here.
In 2028, ICCC is projected to trade between $13.18 and $24.55, averaging $17.36 — a potential gain of +63% from today's $10.63. That is up +25% on the projected 2027 average. Buyers look set to stay in control over this stretch.
ImmuCell Corporation's 2029 outlook centres on $20.41, within a $15.09 to $29.78 range. That is up +18% on the projected 2028 average. That marks a +92% change versus current levels. Momentum favours further upside here.
By 2030, ICCC could reach as high as $41.93, with a base case around $27.99 and support toward $20.21 — roughly +163% from $10.63. Buyers look set to stay in control over this stretch.
Expect ICCC to range from $23.56 to $51.08 through 2031. The $33.33 average target implies a +214% move from current prices. That is up +19% on the projected 2030 average. Momentum favours further upside here.
The ICCC price prediction for 2032 points to an average of $33.86 (low $23.46, high $52.98) — a potential gain of +219% on today's $10.63. Buyers look set to stay in control over this stretch.
In 2033, ICCC is projected to trade between $26.18 and $61.39, averaging $38.50 — a potential gain of +262% from today's $10.63. That is up +14% on the projected 2032 average. Momentum favours further upside here.
ImmuCell Corporation's 2034 outlook centres on $41.15, within a $27.48 to $66.75 range. That is up +7% on the projected 2033 average. That marks a +287% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ICCC could reach as high as $82.91, with a base case around $50.30 and support toward $33.02 — roughly +373% from $10.63. Momentum favours further upside here.
Expect ICCC to range from $48.58 to $141.13 through 2040. The $80.09 average target implies a +653% move from current prices. That is up +59% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ICCC price prediction for 2050 points to an average of $192.57 (low $101.68, high $373.92) — a potential gain of +17.1x on today's $10.63. Momentum favours further upside here.
Investing $1,000 in ICCC today (≈ 94.073377 ICCC) could be worth
$18,115.98
+$17,115.98 (+1712%) by 2050 · US Dollar
Based on the average projected ICCC price of $192.57 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ICCCwould be worth at today's price.
$1,000 invested in ICCC on May 27, 2025 (≈ 160 ICCC) would be worth
$1,700.8
+$700.8 (+70.1%) today · 1.70× · US Dollar
Based on a ICCC entry price of $6.25 vs. today's $10.63.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.88 | $1,075.91 | +7.6% |
| 1 month ago | $8.25 | $1,288.48 | +28.8% |
| 3 months ago | $6.55 | $1,622.9 | +62.3% |
| 6 months ago | $4.84 | $2,196.28 | +119.6% |
| 1 year ago | $6.25 | $1,700.8 | +70.1% |
| All time (5.0y) ago | $9.47 | $1,122.49 | +12.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ICCC forecast.
Our base-case forecast reaches $21.00 around 2030.
Implied market cap at $21.00: $189.98M
The multi-year forecast shows a clear bullish arc for ICCC. In 2026, the min is $5.84, the avg is $10.12, and the max is $14.13, with a 0% ROI and a neutral sentiment. By 2027 the avg climbs to $13.32 with a 31.6% ROI and bullish sentiment, and by 2028 the avg is $16.52 with a 63.3% ROI.
In 2029 the avg reaches $19.49 (92.6% ROI), and in 2030 the avg is $27.18 with a 168.6% ROI and bullish sentiment. The long-range view extends to 2040 (avg $77.39, ROI 664.7%) and 2050 (avg $190.45, ROI 1781.9%), both marked bullish. These figures illustrate a sustained upside path through 2030, 2040, and 2050, though they are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast for 2030 shows min $19.49, avg $27.18, max $41.05 with a 168.6% ROI and bullish sentiment.
Forecasts indicate bullish sentiment from 2027 onward, with rising average prices and ROIs reaching 168.6% by 2030 and 1781.9% by 2050, though these are estimates and not guarantees.
Yes. The 2040 forecast shows a max of $137.98, indicating the possibility of exceeding $100 in that period.
For 2050 the min is $98.31, the avg is $190.45, the max is $374.92, with a ROI of 1781.9% and bullish sentiment.
The current price is $10.12. The 30-day sentiment is BULLISH with RSI14 at 70, the 30-day range is $8.20–$12.50, support is $7.11, and resistance is $10.20.
ImmuCell Corporation Community Discussion
0Share your ImmuCell Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.